Get more help to apply for medicines Integrated Scientific Advice (ISA)

AI Summary

This guidance document details the Integrated Scientific Advice (ISA) service, a collaborative effort between the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE). The program provides medicine developers with a coordinated pathway to receive combined regulatory and health technology assessment (HTA) feedback. By aligning the requirements for market authorization with those for value-based healthcare assessments, the service helps developers streamline their clinical trial designs and evidence-gathering strategies. Although the provided text does not reference a specific company, inspection dates, or regulatory violations, it establishes the framework for early-stage engagement between industry and UK health authorities. To utilize the service, developers must prepare comprehensive briefing documents, formulate specific clinical or economic questions, and pay the required administrative fees. The process culminates in a formal meeting where developers present their plans to a panel of experts from both agencies, followed by the issuance of a detailed advice report. This proactive approach is intended to reduce uncertainty in the development process and ensure that new treatments meet the necessary standards for both safety and cost-effectiveness within the UK healthcare system.